{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T19:38:06Z","timestamp":1760729886446},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,8,6]],"date-time":"2007-08-06T00:00:00Z","timestamp":1186358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Geriat Psychiatry"],"published-print":{"date-parts":[[2008,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To describe patterns of Acetylcholinesterase inhibitor (ACI) use in an Assisted Living (AL) population, and the association of ACIs with retention in AL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>As part of the Maryland Assisted Living Study (MD\u2013AL), 198 residents of 22 ALs were evaluated. Dementia was diagnosed in 134, and specifically Alzheimer's disease (AD) in 79, by an expert consensus panel. Data was collected on ACI agent and dose. Vital status and location were recorded every 6 months. Other data included age, duration of residence, general medical health rating (GHMR), Mini\u2010Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Cornell Scale for Depression in Dementia (CSDD) and number of non\u2010psychiatric medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall ACI treatment rate was 31%. 34.5% of participants with mild to moderate AD were taking ACIs. Only two in seven participants taking rivastigmine were taking an adequate dose. Participants with AD on ACI's did not differ significantly from those not on ACI's in any of the secondary measures except age and duration of residence, those on the agents being somewhat younger and more recently admitted. For participants with AD, only ACI use was significantly associated with retention in AL at 6 months, with a relative risk of death or discharge to higher level care of 0.217. Baseline MMSE was associated with retention for those with non\u2010AD dementia. In a survival analysis ACI use was associated with 228.75 days longer retention in participants with AD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ACIs have low rates of use in AL and are associated with better retention for residents with AD. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/gps.1859","type":"journal-article","created":{"date-parts":[[2007,8,6]],"date-time":"2007-08-06T09:17:32Z","timestamp":1186391852000},"page":"178-184","source":"Crossref","is-referenced-by-count":9,"title":["Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention"],"prefix":"10.1002","volume":"23","author":[{"given":"Adam","family":"Rosenblatt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quincy M.","family":"Samus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiadi U.","family":"Onyike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alva S.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"McNabney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence S.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantine G.","family":"Lyketsos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,6]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16499-4"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(88)90038-8"},{"key":"e_1_2_1_4_1","first-page":"224","volume-title":"Assisted Living","author":"Bernard SL","year":"2001"},{"key":"e_1_2_1_5_1","first-page":"55","article-title":"A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease","volume":"1","author":"Corey\u2010Bloom J","year":"1998","journal-title":"Int J Ger Psychopharmacol"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.12.2308"},{"key":"e_1_2_1_7_1","first-page":"A468","article-title":"Rivastigmine provides behavioral benefits to Alzheimer's disease patients residing in a nursing home: findings from a 26\u2010 week trial","volume":"54","author":"Cummings JL","year":"2000","journal-title":"Neurology"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-200005000-00008"},{"key":"e_1_2_1_9_1","first-page":"189","article-title":"\u2018Mini\u2010Mental State\u2019: a practical method for grading the cognitive state of patients for the clinician","volume":"2","author":"Folstein MF","year":"1975","journal-title":"J Psychiatric Res"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2389.2003.51306.x"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-199821001-00002"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000129990.32253.7B"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53015.x"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1999.tb07245.x"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291700038484"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.3.481"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.7.939"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.2.250"},{"key":"e_1_2_1_19_1","unstructured":"National Center for Assisted Living.2001.Facts and Trends: The Assisted Living Sourcebook. NCAL."},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1990.tb01601.x"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2004.52452.x"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.12.2269"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000078943.50032.FC"}],"container-title":["International Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fgps.1859","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/gps.1859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T13:17:20Z","timestamp":1699967840000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/gps.1859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,6]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["10.1002\/gps.1859"],"URL":"https:\/\/doi.org\/10.1002\/gps.1859","archive":["Portico"],"relation":{},"ISSN":["0885-6230","1099-1166"],"issn-type":[{"value":"0885-6230","type":"print"},{"value":"1099-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,6]]}}}